Results 11 to 20 of about 24,077 (195)

The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms

Haematologica, 2011
Background Myeloproliferative neoplasms constitute a group of diverse chronic myeloid malignancies that share pathogenic features such as acquired mutations in the JAK2, TET2, CBL and MPL genes.
Damla Olcaydu, Elisa Rumi, Ashot Harutyunyan, Francesco Passamonti, Daniela Pietra, Cristiana Pascutto, Tiina Berg, Roland Jäger, Emma Hammond, Mario Cazzola, Robert Kralovics   +10 more
doaj   +1 more source

Chronic myeloproliferative disorders: A rarest case with oral manifestations and dental management

Journal of Indian Academy of Oral Medicine and Radiology, 2012
Chronic myeloproliferative disorders (CMPD) are rarest hematological disorders (malignant myeloid neoplasms). The three most common chronic myeloproliferative disorders are polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Pritesh B Ruparelia, Kosha Pritesh Ruparelia, Rajan Shirolkar, Anurag Tripathi   +3 more
doaj   +1 more source

Bone Marrow Fibrosis in Chronic myeloid leukemia (CML) and other Myeloproliferative Disorders Evaluated by Using Special Histochemical Stains for Collagen.

مجلة كلية الطب, 2011
Background: It is still difficult to give a final diagnosis in chronic myeloproliferative disorders (CMPDs) because of the overlap of the common pathological and clinical features of these disorders like bone marrow fibrosis which is considered important
Ali Khalil I. Al-Khafaji, Haider H. Jaleel Al-Shammari, Salim R. Hamudi Al-Obeidi   +2 more
doaj   +1 more source

JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury

Haematologica, 2018
Myeloproliferative neoplasms are clonal stem cell disorders characterized by hematopoietic stem/progenitor cell expansion. The acquired kinase mutation JAK2V617F plays a central role in these disorders.
Chi Hua Sarah Lin, Yu Zhang, Kenneth Kaushansky, Huichun Zhan   +3 more
doaj   +1 more source

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders

Haematologica, 2008
Background The JAK2 V617F mutation can be found in patients with polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis. Mutation or methylation of other components of JAK/STAT signaling, such as the negative regulators suppressor of ...
Nasios Fourouclas, Juan Li, Daniel C. Gilby, Peter J. Campbell, Philip A. Beer, Elaine M. Boyd, Anne C. Goodeve, David Bareford, Claire N. Harrison, John T. Reilly, Anthony R. Green, Anthony J. Bench   +11 more
doaj   +1 more source

A rare case of late myelodysplasia cutis associated with essential thrombocythemia: A case report

SAGE Open Medical Case Reports, 2022
Myelodysplasia cutis is a relatively new described entity that is characterized by cutaneous plaques and nodules representing dermal infiltration of myeloid immature non-blastic cells.
Suzel Fournier, Sylvain Mailhot, Janie Bujold   +2 more
doaj   +1 more source

Oncogenes in Myeloproliferative Disorders [PDF]

Cell Cycle, 2007
Myeloproliferative disorders (MPDs) constitute a group of hematopoietic malignancies that feature enhanced proliferation and survival of one or more myeloid lineage cells. William Dameshek is credited for introducing the term "MPDs" in 1951 when he used it to group chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET ...
Ayalew, Tefferi, D Gary, Gilliland
openaire   +2 more sources

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia

Indian Journal of Medical and Paediatric Oncology, 2015
According to the 2008 revision of the World Health Organization (WHO) classification of myeloid malignancies, philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) include clonal, hematologic disorders such as polycythemia vera ...
M B Agarwal, Hemant Malhotra, Prantar Chakrabarti, Neelam Varma, Vikram Mathews, Jina Bhattacharyya, Tulika Seth, K Gayathri, Hari Menon, P G Subramanian, Ajay Sharma, Maitreyee Bhattacharyya, Jay Mehta, A K Vaid, Sandeep Shah, Shyam Aggarwal, P K Gogoi, Reena Nair, Usha Agarwal, Subhash Varma, S. V. S. S. Prasad, Marie Therese Manipadam   +21 more
doaj   +1 more source

Failure of Splenectomy to Ameliorate Portal Hypertension in Myeloproliferative Disorders

Canadian Journal of Gastroenterology, 1994
The correct treatment of portal hypertension associated with myeloproliferative disorders remains uncertain. Splenectomy has been advocated by some to eliminate the forward flow component of the portal hypertension and thus reduce portal pressure.
Samuel S Lee, Guido Van Rosendaal, Thomas E Lay, James K Kelly, Graham F Pineo   +4 more
doaj   +1 more source

Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

BMC Medical Genomics, 2019
Background Approximately 5–20% of chronic myeloid leukemia (CML) patients demonstrate primary resistance or intolerance to imatinib. None of the existing predictive scores gives a good prognosis of TKI efficacy.
Alexander V. Lavrov, Ekaterina Yu. Chelysheva, Elmira P. Adilgereeva, Oleg A. Shukhov, Svetlana A. Smirnikhina, Konstantin S. Kochergin-Nikitsky, Valentina D. Yakushina, Grigory A. Tsaur, Sergey V. Mordanov, Anna G. Turkina, Sergey I. Kutsev   +10 more
doaj   +1 more source